The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of silver nanoparticles against *Staphylococcus aureus*

Prashik Parvekar, Jayant Palaskar, Sandeep Metgud, Rahul Maria & Smita Dutta

To cite this article: Prashik Parvekar, Jayant Palaskar, Sandeep Metgud, Rahul Maria & Smita Dutta (2020) The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of silver nanoparticles against *Staphylococcus aureus*, Biomaterial Investigations in Dentistry, 7:1, 105-109, DOI: 10.1080/26415275.2020.1796674

To link to this article: https://doi.org/10.1080/26415275.2020.1796674

© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

Published online: 23 Jul 2020.

Submit your article to this journal

Article views: 358

View related articles

View Crossmark data
The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of silver nanoparticles against *Staphylococcus aureus*

Prashik Parvekar, Jayant Palaskar, Sandeep Metgud, Rahul Maria and Smita Dutta

Aim: To determine the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of silver nanoparticles against *Staphylococcus aureus* (*S. aureus*).

Methodology: The antimicrobial efficacy of the silver nanoparticles was determined by the standard methods of Clinical and Laboratory Standards Institute (CLSI). Different concentrations of silver nanoparticles were prepared, and MIC was calculated by tube macro-dilution method. The MBC was determined by the lowest concentration that kills 99.9% of the initial bacterial population. The data were analyzed by ANOVA and Tukey’s post hoc test using SPSS software.

Results: The MIC and MBC of silver nanoparticles against *S. aureus* was found to be 0.625 mg/ml.

Conclusion: The result obtained from this study shows that silver nanoparticles have potential bactericidal effects against *S. aureus* at a concentration of 0.625 mg/ml. Silver nanoparticles can be incorporated in the root canal medicaments, sealers and irrigants as it possess potent antimicrobial efficacy against *S. aureus*.

Introduction

*Staphylococcus aureus* is a facultative anaerobic, immobile, nonsporulated, gram positive coccus, which is a source of periodontal, periapical, and endodontic infections. It is a minor component of oral micro biota but frequently present in the oral cavity and perioral region [1,2]. It is one of the important resistant microorganisms and is frequently associated with failed root canal treatments. Along with *Enterococcus faecalis*, *Streptococcus mitis*, *Prevotella* spp. and *Porphyromonas endodontalis*, it plays a role in causing primary and secondary root canal infections [3,4]. It is responsible for a variety of human infections including superficial lesions in the skin and localized abscesses, central nervous system infections, osteomyelitis, invasive endocarditis, septic arthritis, sepsis, pneumonia, and urinary tract infections [5]. Mortality due to bacteremia caused by *S. aureus* is between 13% and 26% [6].

Antibacterial properties of silver have been known since ancient times. Silver vessels were used to preserve water, which was later attributed to the fact that silver ions inhibit bacterial growth by intervening the bacterial DNA functions [7]. Silver in a nanometric scale (less than 100 nm) has different antibacterial properties compared with bulk form of silver metal, like a large effective surface area of individual silver nanoparticles and strong toxicity to a wide range of microorganisms [8].

Previous studies have investigated the antibacterial effect of silver nanoparticles on both gram-positive and gram-negative bacteria such as *S. aureus*, *Escherichia coli*, *Pseudomonas aeruginosa* and *Staphylococcus epidermid* [9,10]. MIC and MBC of 5 nm silver nanoparticles on *S. aureus* is yet to be established. The aim of the present study was to assess the antimicrobial efficacy of silver nanoparticles against *S. aureus* by determining both MIC and MBC.

Materials

Silver nanoparticles formulation

Silver nanoparticles of an average particle size of 5 nm were procured from nanoComposix San Diego, USA,
in a solution form. The stock solution was used to prepare six different concentrations of 5, 2.5, 1.25, 0.625, 0.312 and 0.156 mg/ml.

**S. aureus strain, medium, and cultivation**

The revived ampoule of *S. aureus* (ATCC: 25923) bacteria was centrifuged at 11,000 rpm for 5 min in BHI broth. 20 ml of sterile normal saline was added after discarding the supernatant. The remaining bacterial precipitate was viable and maintained as stock. Then, the concentration was adjusted by spectrophotometer to an optical density of 0.10 at 625 nm (10^8 CFU/ml, 0.5 McFarland’s standard).

**Methodology**

**MIC determination**

The standard broth dilution method (CLSI M07-A8) was used to study the antimicrobial efficacy of silver nanoparticles by evaluating the visible growth of microorganisms in the agar broth. Serial two-fold dilutions of silver nanoparticles in concentrations ranging from 5 mg/ml to 0.156 mg/ml with adjusted bacterial concentration (10^8 CFU/ml, 0.5 McFarland’s standard) were used to determine MIC in BHI broth. The control contained only inoculated broth and incubated for 24 h at 37°C. The MIC endpoint is the lowest concentration of silver nanoparticles where no visible growth is seen in the tubes. The visual turbidity of the tubes was noted, both before and after incubation to confirm the MIC value.

**MBC determination**

After the MIC determination of the silver nanoparticles, aliquots of 50 µl from all the tubes which showed no visible bacterial growth were seeded on BHI agar plates and incubated for 24 h at 37°C. When 99.9% of the bacterial population is killed at the lowest concentration of an antimicrobial agent, it is termed as MBC endpoint. This was done by observing pre and post-incubated agar plates for the presence or absence of bacteria.

**Statistical analysis**

The MBC result was analyzed by ANOVA using descriptive statistics including mean and standard deviation. Tukey’s post hoc test was done for the analysis of MBC of silver nanoparticles against *S. aureus*. Significance of all the statistical tests was predetermined at p < .05.

**Result**

**Observations for Staphylococcus aureus**

After 24 h of incubation under aerobic conditions at 37°C, turbidity was noticed in the test tubes 0.156 and 0.312 mg/ml containing silver nanoparticles indicating the growth of bacteria. Whereas in concentrations of 0.625, 1.25, 2.5, 5 mg/ml, no turbidity was seen, exhibiting inhibition of bacterial growth.

The suspension from the tubes of 0.625, 1.25, 2.5, 5 mg/ml was inoculated in BHI agar plate and incubated for 24 h and no growth of bacteria was observed in all the concentrations hence confirming it as bactericidal.

Statistical analysis by ANOVA and Tukey’s post hoc test of MBC for different concentrations when assessed for *S. aureus* showed significant inhibition of growth both for 0.625, 1.25, 2.5, 5 mg/ml when compared to 0.156 and 0.312 mg/ml, and the MIC was obtained at 0.625 mg/ml. These results thus confirm that the MIC and MBC of silver nanoparticles for *S. aureus* was found to be effective at dilution of 0.625 mg/ml.

**Discussion**

This study was aimed at determining the MIC and MBC of silver nanoparticles against *S. aureus*. The antibacterial effects of drugs are routinely assessed by agar diffusion and MIC test. The advantage of direct contact tests over the agar diffusion method is that it is independent of the diffusion properties of the tested material and media [11]. Serial dilutions of a solution are used for MIC to determine the lowest concentration of material that would still show antibacterial properties.

*Staphylococcus aureus*, a facultative anaerobic gram-positive coccus, has been recovered from several oral sites [12]. It was selected for use in this study because it is one of the facultative bacteria found in failed root canal cases and recurrent apical periodontitis [13] and it can develop resistance to antimicrobial agents.

The antimicrobial effects of silver are mostly attributed to silver ions [14,15]. Silver nanoparticles continuously release silver ions in an aqueous microenvironment [16]. Because of the bigger surface area of silver nanoparticles, they show a stronger and better bactericidal effect [17]. The main reasons for
bactericidal properties of silver nanoparticles are interfering with the integrity of the bacterial cell by binding to essential cellular structural [18], particularly to their SH-groups [19,20]. Silver nanoparticles also generate reactive oxygen species (ROS) and free radicals which damage the bacterial cell wall and inhibit the respiratory enzymes [21]. Silver nanoparticles disturb the DNA replication and terminate the bacteria. Silver nanoparticles are biocidal to various gram-positive and gram-negative bacteria [22].

In this study, MIC and MBC of silver nanoparticles against S. aureus were determined by macrodilution method and both were found to be effective at 0.625 mg/ml. (Tables 1 and 2) This is the first study in the literature to include the MBC of 5 nm silver nanoparticles against S. aureus. One study demonstrated that MIC, MBC of 10 nm silver nanoparticles is in concentrations of 1.35 mg/ml against S. aureus. [23] This variation might be due to the methodology used to prepare silver nanoparticles and the size of the silver nanoparticles used. The ultrafine particle size causes its action at lower concentration. In this study commercially available silver nanoparticle was used with the size of 5 nm. Silver nanoparticles with less than 10 nm sizes showed an enhanced antimicrobial effect in a study by Agnihotri et al. They also concluded that compared to other sizes of silver nanoparticles, 5 nm size have the fastest antibacterial activity [24].

Humberto et al. in their study found that silver nanoparticles are effective broad-spectrum biocides against a variety of drug-resistant bacteria [25]. Various studies have concluded that silver nanoparticles possess antimicrobial effect against many bacteria and fungi, including S. mutans, C. albicans, P. aeruginosa, E. faecalis, and S. aureus, among others, which could decrease the occurrence of secondary caries, fungical infection, endodontic failure, and dental implant losses [26]. Generally, the tendency to develop bacterial resistance is low towards noble metals [27]. Ellis et al. concluded in their study that P. aeruginosa was able to develop resistance to silver nanoparticles while S. aureus and A. baumannii did not develop resistance to silver nanoparticles [28]. Hosny et al. detected plasmid-mediated silver resistance in clinical bacteria like P. aeruginosa, A. baumannii and S. aureus isolates [29]. Results from Kaweeetearawat et al. study suggested that silver nanoparticles enhanced the bacterial resistance to antibiotics by promoting stress tolerance through induction of intracellular ROS [30]. It is worth noting, however, that most of the studies are related to exogenous and endogenous silver ion resistance. The release of silver ions by silver nanoparticles is only one of the forms by which silver nanoparticles act as an antimicrobial, as discussed earlier [31]. One side effect of silver is argyria, an irreversible pigmentation of the skin that is mostly an aesthetic concern [32]. Silver nanoparticles also display substantial toxicity against fibroblasts, hepatocytes, osteoblasts or bone-marrow cells [33].

An important limitation of this study is that it was done on planktonic bacteria. The dental infections are mostly polymicrobial, consisting of Enterococcus, Streptococci, Provotella, Porphyromonas and many more bacteria. They present different properties in biofilm. Further study is required to assess the antimicrobial effect of silver nanoparticles on dental biofilm.

Most of the time, in-vitro results do not correlate with in-vivo activity. The results obtained from this study suggest that the effective bactericidal concentration of silver nanoparticles against S. aureus is 0.625 mg/ml. The use of silver nanoparticles as an antimicrobial agent against S. aureus is possible. Silver nanoparticles can be incorporated into the intra-canal medicaments, root canal sealers and also in irrigating solution to eradicate S. aureus from the root canal.

### Table 1. Minimum inhibitory concentration (MIC), turbidity for different concentrations of silver nanoparticles after 24 h.

| Dilution of silver nanoparticles | 5 mg/ml | 2.5 mg/ml | 1.25 mg/ml | 0.625 mg/ml | 0.312 mg/ml | 0.156 mg/ml |
|----------------------------------|---------|-----------|------------|-------------|-------------|-------------|
|                                  | 0.05%   | 0.25%     | 0.12%      | 0.06%       | 0.03%       | 0.01%       |
| Set 1                            | –       | –         | –          | –           | –           | –           |
| Set 2                            | –       | –         | –          | –           | –           | –           |
| Set 3                            | –       | –         | –          | –           | –           | –           |
| Set 4                            | –       | –         | –          | –           | –           | –           |
| Set 5                            | –       | –         | –          | –           | –           | –           |

Positive (+): Turbidity indicating growth; Negative (−): No turbidity indicating absence of growth.

### Table 2. Minimum Bactericidal Concentrations (MBC) of silver nanoparticles after 24 h.

| Dilution of silver nanoparticles | 5 mg/ml | 2.5 mg/ml | 1.25 mg/ml | 0.625 mg/ml |
|----------------------------------|---------|-----------|------------|-------------|
|                                  | 0.05%   | 0.25%     | 0.12%      | 0.06%       |
| Set 1                            | –       | –         | –          | –           |
| Set 2                            | –       | –         | –          | –           |
| Set 3                            | –       | –         | –          | –           |
| Set 4                            | –       | –         | –          | –           |
| Set 5                            | –       | –         | –          | –           |

Positive (+): Indicating growth; Negative (−): Indicating absence of growth.
increasing the success rate of root canal treatments. Future in vivo studies are needed to imply this effectively. Future scope of antimicrobial silver nanoparticles in contemporary dentistry includes wide ranges of applications in restorative dentistry, endodontics, implantology, dental prostheses, orthodontics and other dental fields.

Disclosure statement

No potential conflict of interest was reported by the author(s).

References

[1] Pinheiro ET, Gomes BP, Ferraz CC, et al. Microorganisms from canals of rootfilled teeth with periapical lesions. Int Endod J. 2003;36(1):1–11.
[2] McCormack MG, Smith AJ, Akram AN, et al. *Staphylococcus aureus* and the oral cavity: an overlooked source of carriage and infection?. Am J Infect Control. 2015;43(1):35–37.
[3] Jhajharia K, Parolia A, Shetty KV, et al. Biofilm in endodontics: a review. J Int Soc Prev Community Dent. 2015;5(1):1–12.
[4] Shah S, Venkataramakhan K, Choudhary P, et al. Evaluation of antimicrobial effect of azadirachtin plant extract (Soluneeem (TM)) on commonly found root canal pathogenic microorganisms (viz. Enterococcus faecalis) in primary teeth: a microbiological study. J Indian Soc Pedod Prev Dent. 2016;34(3):210–216.
[5] Velazquez-Meza ME. *Staphylococcus aureus* methicillin-resistant: emergence and dissemination. Salud Publica Mex. 2005;47:381–387.
[6] Austin ED, Sullivan SS, Macesic N, et al. Reduced mortality of *Staphylococcus aureus* bacteremia in a retrospective cohort study of 2139 patients: 2007–2015. Clin Infect Dis. 2020;70(8):1666–1674.
[7] Li Y, Leung P, Yao L, et al. Antimicrobial effect of surgical masks coated with nanoparticles. J Hosp Infect. 2006;62(1):58–63.
[8] Elechiguerra JL, Burt JL, Morones JR, et al. Interaction of silver nanoparticles with HIV-1. J Nanobiotechnol. 2005;3:6.
[9] Feng QL, Wu J, Chen GQ, et al. A mechanistic study of the antibacterial effect of silver ions on *Escherichia coli* and *Staphylococcus aureus*. J Biomed Mater Res. 2000;52(4):662–668.
[10] Ha-Hymn Y, Hye-Kyoun J, Young-Jung J, et al. *Enterococcus faecalis* activates caspase-1 leading to increased interleukin-1 beta secretion in macrophages. J Endod. 2014;40(10):1587–1592.
[11] Estrela C, Rodrigues de Araújo Estrela C, Bammann LL, et al. Two methods to evaluate the antimicrobial action of calcium hydroxide paste. J Endod. 2001;27(12):720–723.
[12] Shweta, Prakash SK. Dental abscess: a microbiological review. Dent Res J. 2013;10(5):585–591.
[13] Haapasalo M, Udnaes T, Endal U. Persistent, recurrent, and acquired infection of the root canal system post-treatment. Endodontic Topics. 2003;6(1):29–56.
[14] Chen X, Schluesener HJ. Nanosilver: a nanoproduct in medical application. Toxicol Lett. 2008;176(1):1–12.
[15] Matsumura Y, Yoshikata K, Kunisaki S, et al. Mode of bactericidal action of silver zeolite and its comparison with that of silver nitrate. Appl Environ Microbiol. 2003;69(7):4278–4281.
[16] Lok CN, Ho CM, Chen R, et al. Silver nanoparticles: partial oxidation and antibacterial activities. J Biol Inorg Chem. 2007;12(4):527–534.
[17] Doty C, Tshikhudo R, Brust M, et al. Extremely stable water-soluble Ag nanoparticles. Chem Mater. 2005;17(18):4630–4635.
[18] Mackar S, Aggarwal A, Pasricha S, et al. To evaluate the antibacterial properties of silver nano particle based irrigant as endodontic root canal irrigant. Int J Dent Health Sci. 2014;1(4):485–492.
[19] Morones JR, Elechiguerra JL, Camacho A, et al. The bactericidal effect of silver nanoparticles. Nanotechnology. 2005;16(10):2346–2353.
[20] Zhou Y, Kong Y, Kundu S, et al. Antibacterial activities of gold and silver nanoparticles against *Escherichia coli* and bacillus Calmette-Guérin. J Nanobiotechnol. 2012;10(1):19.
[21] Loo YY, Rukayadi Y, Nor-Khaizura M-A-R, et al. In vitro antimicrobial activity of green synthesized silver nanoparticles against selected gram-negative foodborn pathogens. Front Microbiol. 2018;9(1555):1–7.
[22] Prabhu S, Poulouse EK. Silver nanoparticles: mechanism of antimicrobial action, synthesis, medical applications, and toxicity effects. Int Nano Lett. 2012;2(1):32.
[23] Vanesa Ayala-Nuñez N, Lara Villegas HH, del Carmen Ixtepan Turrent L, et al. Silver nanoparticles toxicity and bactericidal effect against methicillin-resistant *Staphylococcus aureus*: Nanoscale does matter. Nanobiotechnol. 2009;5(1–4):2–9.
[24] Agnihotri S, Mukherji S, Mukherji S. Size-controlled silver nanoparticles synthesized over the range 5–100 nm using the same protocol and their antibacterial efficacy. RSC Adv. 2014;4(8):3974–3983.
[25] Lara HH, Garza-Treviño EN, Ixtepan-Turrent L, et al. Silver nanoparticles are broad-spectrum bactericidal and virucidal compounds. J Nanobiotechnology. 2011;9:30.
[26] Corrêa JM, Mori M, Sanches HL, et al. Silver nanoparticles in dental biomaterials. Int J Biomat .2015;2015:1–9.
[27] Ip M, Lui SL, Poon VK, et al. Antimicrobial activities of silver dressings: an in vitro comparison. J Med Microbiol. 2006;55(Pt 1):59–63.
[28] Ellis DH, Maurer-Gardner EJ, Suletic CEW, et al. Silver nanoparticle antibacterial efficacy and
resistance development in key bacterial species. Biomed Phys Eng Express. 2018;5(1):015013.

[29] Hosny A, Rasmy SA, Aboul-Magd DS, et al. The increasing threat of silver-resistance in clinical isolates from wounds and burns. Infect Drug Resist. 2019;12:1985–2001.

[30] Kaweeteerawat C, Na Ubol P, Sangmuang S, et al. Mechanisms of antibiotic resistance in bacteria mediated by silver nanoparticles. J Toxicol Environ Health. 2017;80:23–24.

[31] Barros CHN, Fulaz S, Stanisic D, et al. Biogenic nanosilver against multidrug-resistant bacteria (MDRB). Antibiotics. 2018;7(3):69.

[32] Drake PL, Hazelwood KJ. Exposure-related health effects of silver and silver compounds: a review. Ann Occup Hyg. 2005;49(7):575–585.

[33] Prasher P, Singh M, Mudila H. Silver nanoparticles as antimicrobial therapeutics: current perspectives and future challenges. 3 Biotech. 2018;8(10):411.